NATCO Pharma Ltd has approved the acquisition of an additional stake in South Africa-based Adcock Ingram Holdings Proprietary Limited, increasing its shareholding from 35.75% to 49% in a transaction valued at approximately Rs. 1,069 crore.

The decision was approved by the company's Board of Directors and remains subject to customary closing conditions and statutory approvals.

The acquisition strengthens NATCO Pharma's strategic presence in the African pharmaceutical market through Adcock Ingram, one of South Africa's leading pharmaceutical manufacturers and healthcare companies.

According to the company, Adcock Ingram reported revenue of US$423 million and an EBITDA of approximately US$59 million for the nine-month period ended March 31, 2026.

Following completion of the transaction, NATCO will account for 49% of Adcock Ingram's profit after tax in its financial statements, reflecting the increased equity participation.

The investment is expected to enhance NATCO's long-term international growth strategy by expanding its exposure to regulated and emerging markets while strengthening earnings contribution from its overseas investments.

NATCO Pharma said the transaction is subject to customary closing conditions and the necessary statutory and regulatory compliances before completion.